Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Whitaker

Physical Medicine & Rehabilitation Boise, ID Doctor of Osteopathy

NPI 1750692562 CMS profile 669925

1760 N Mitchell St, Boise, ID 83704

Open in the dashboard

General payments

$4,370

223 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Whitaker of Boise, ID is reported in the CMS Open Payments database as having received $4,370 across 223 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $736 34
2024 General $844 36
2023 General $726 30
2022 General $631 36
2021 General $828 53
2020 General $278 17
2019 General $327 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Whitaker
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to James Whitaker were reported at $736. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year James Whitaker Physical Medicine & Rehabilitation median Middle half National median
2019 $327 $133 $45–$390 $163
2020 $278 $88 $29–$272 $114
2021 $828 $116 $33–$360 $132
2022 $631 $123 $40–$378 $149
2023 $726 $131 $43–$396 $160
2024 $844 $141 $45–$409 $164
2025 $736 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,805 88 payments
  2. Lilly USA, LLC $440 29 payments
  3. Amgen Inc. $368 18 payments
  4. Teva Pharmaceuticals USA, Inc. $364 22 payments
  5. Collegium Pharmaceutical, Inc. $202 13 payments
  6. Pfizer Inc. $176 12 payments
  7. Upsher-Smith Laboratories LLC $174 9 payments
  8. Boston Scientific Corporation $173 2 payments
  9. Nevro Corp. $124 2 payments
  10. Biodelivery Sciences International, Inc. $78 5 payments
  11. Other $467 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,370 223 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,110 56 payments
  2. QULIPTA $1,092 55 payments
  3. EMGALITY $440 29 payments
  4. REYVOW $388 26 payments
  5. AIMOVIG $338 17 payments
  6. BOTOX $260 14 payments
  7. AJOVY $226 13 payments
  8. XTAMPZA $185 12 payments
  9. NURTEC ODT $176 12 payments
  10. TOSYMRA $157 8 payments
  11. Other $1,504 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,372

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$41,492

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

28.9%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 28 $9,004
Pregabalin Generic 144 $6,341
Xtampza Er Oxycodone Myristate Brand 12 $5,716
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 216 $4,577
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 134 $3,710
Oxycodone Hcl Generic 128 $2,535
Gabapentin Generic 94 $1,810
Fentanyl Generic 11 $1,711
Tramadol Hcl Generic 126 $1,400
Naloxone Hcl Generic 12 $885

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$73,727

Of which drugs: $16,137

Medicare patients

130

Average age 70

Services billed

4,088

81 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 51%
Depression 28%
Osteoporosis 22%
Diabetes 19%
Chronic kidney disease 16%
Atrial fibrillation 15%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 14 1,040 $7,131
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 60 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $254
$254 — —
UBRELVY
  • AbbVie, Inc. $233
$233 — —
QULIPTA
  • AbbVie, Inc. $210
$210 — —
AJOVY
  • Teva Pharmaceuticals USA, Inc. $25
$25 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

223 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record